You are on page 1of 4

SMi’s 10th Annual RNA Therapeutics Returns to London This February 2019

London, United Kingdom, September 26, 2018 --(PR.com)-- SMi Group announces the 10th Annual
RNA Therapeutics Conference in London on February 20th - 21st 2019. Undoubtedly, the field of RNA
therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for
personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases
will ensure the continued development of RNA therapeutics for years to come.

Fulfilling the potential of genetic discoveries requires the development of therapeutics that can
specifically modulate the expression of disease-relevant genes. RNA-based drugs, including siRNAs and
antisense nucleotides, are promising examples of a newer class of biologics. Researchers have tried to
overcome the major challenges for utilising RNAs in a therapeutic context, including: intracellular
delivery, stability and immunogenicity.

Join SMi Group in February 2019, for SMi's 10th annual sell out conference, RNA Therapeutics.
Bringing together industry experts from leading RNA companies, to discuss the challenges for clinical
translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and
present an overview of the applications of RNA-based drugs for modulation of gene and protein
expression, and genome editing.

Network and learn from key opinion leaders such as:

Chair's for 2019:

- Ekkehard Leberer, Senior Director, Alliance Management, Sanofi


- Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca

Keynote Speakers:

- Carsten Rudolf, Chief Executive Officer, Ethris Gmbh


- Paul Agris, Founder and Director, The RNA Institute
- Marian Gindy, Executive Director, Pharmaceutical Sciences, Merck Research Labs, Merck & Co, inc.
- David Giljohan, CEO, Exicure
- Ingmar Hoerr, Founder & CEO, CureVac AG
- David Blakey, Chief Scientific Officer, MiNA Therapeutics
- André Gerber, Professor of RNA Biology, University of Surrey
- Heinrich Haas, Vice President Drug Delivery, BioNTech RNA Pharmaceuticals
- Markus Mandler, Chief Scientific Officer, Accanis Biotech
- Troels Koch, Vice President & Head of Research, RNA Therapeutics, Roche
- Hans Kistemaker, Associate Director, ProQR

2019 Featured Highlights:

Page 1/4
PR.com Press Release Distribution Terms of Use
- Discover the clinical progress of Spherical Nucleic Acids at Exicure
- Understand Sanofi's strategies to deliver therapeutic oligonucleotides across biobarriers
- Learn from ProQR how to plan for oligonucleotide supply from personalized medicine to large scale
markets
- Explore the development of small activating RNA - from bench to bedside with MiNA Therapeutics
- Gain insight into the discovery and development of self-amplifying mRNA vaccines at GSK

Download a value-packed brochure online: www.therapeutics-rna.com/prc

A few of last year's attendees:

Accanis Therapeutics | Accent Therapeutics | Advanced Cell Diagnostics SRL | Aldevron | Arrowhead
Pharmaceuticals, Inc. | Arsanis Biosciences GmbH | Arsanis Inc | AstraZeneca | AstraZeneca plc | Bayer /
NOF Europe GmbH | BianoGMP | BioNTech AG | Boehringer Ingelheim Pharma GmbH & Co. | KG |
Chemgenes Corporation | CureVac GmbH | Dicerna Pharmaceuticals, Inc. | Evonik Nutrition & Care
GmbH | Future Medicine Ltd | GSK | Heptares Therapeutics | Hoffmann Eitle | InteRNA Technologies |
Janssen Vaccines & Prevention | LGC | Life Technologies AS | Lipocalyx | Manchester University |
MHRA | MiNA Therapeutics | Moderna Therapeutics | N4 Pharma UK Limited | NEUWAY Pharma
GmbH | Phion Therapeutics Ltd | ProQR Therapeutics | ROCHE | Sanofi-Aventis Deutschland GmbH |
Southeast University | Storm Therapeutics | Sygnature Discovery | Synthetic Genomics Inc | TCR
Solutions | The Italian Institute of Technology | The RNA Institute | The RNA Medicines Company |
Universita Magna Graecia - Catanzaro | University College London | University of Edinburgh | University
Of Glasgow | University of Rennes 1 | University Of Twente / 20Med | Vivomicx

Download the full attendee list in the download centre: www.therapeutics-rna.com/prc

For those looking to attend, there is currently a £400 early-bird saving, only valid online. Register today

Follow "SMi Pharma" on LinkedIn for latest pharmaceutical industry updates.

SMi Presents the 10th annual conference:


RNA Therapeutics
Date: 20th - 21st February 2019
Location: Copthorne Tara Hotel, London UK
Website: www.therapeutics-rna.com/prc

Contact Information:

For all media inquiries contact Pav Solanki on Tel: +44 (0)20 7827 6048 / Email:
psolanki@smi-online.co.uk

About SMi Group:

Page 2/4
PR.com Press Release Distribution Terms of Use
Established since 1993, the SMi Group is a global event-production company that specializes in
Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and
deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We
pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries,
allowing us to bring our communities together to Learn, Engage, Share and Network. More information
can be found at http://www.smi-online.co.uk

Page 3/4
PR.com Press Release Distribution Terms of Use
Contact Information:
SMi Group
Pav Solanki
+4402078276000
Contact via Email
http://www.therapeutics-rna.com/prc

Online Version of Press Release:


You can read the online version of this press release at: https://www.pr.com/press-release/765802

Page 4/4
PR.com Press Release Distribution Terms of Use